Format

Send to

Choose Destination
BMC Med. 2012 Mar 9;10:25. doi: 10.1186/1741-7015-10-25.

Advances in using PARP inhibitors to treat cancer.

Author information

1
Division of Cancer Treatment and Diagnosis, 31 Center Drive, National Cancer Institute, Bethesda, MD 20892, USA.

Abstract

The poly (ADP-ribose) polymerase (PARP) family of enzymes plays a critical role in the maintenance of DNA integrity as part of the base excision pathway of DNA repair. PARP1 is overexpressed in a variety of cancers, and its expression has been associated with overall prognosis in cancer, especially breast cancer. A series of new therapeutic agents that are potent inhibitors of the PARP1 and PARP2 isoforms have demonstrated important clinical activity in patients with breast or ovarian cancers that are caused by mutations in either the BRCA1 or 2 genes. Results from such studies may define a new therapeutic paradigm, wherein simultaneous loss of the capacity to repair DNA damage may have antitumor activity in itself, as well as enhance the antineoplastic potential of cytotoxic chemotherapeutic agents.

PMID:
22401667
PMCID:
PMC3312820
DOI:
10.1186/1741-7015-10-25
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center